Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 5/20 | 0.34 |
| ▸ | THRB | P10828 | 5/20 | 0.34 |
| ▸ | DPP4 | P27487 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | PDE5A | O76074 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | RECQL | P46063 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5232392 | 0.97 | THRB (0.36) | THRATHRBDPP4ALDH1A1POLB | |
| SCHEMBL5238218 | 0.91 | ALDH1A1 (0.33) | THRATHRBALDH1A1HTT | |
| SCHEMBL5236301 | 0.86 | ALDH1A1 (0.42) | THRATHRBALDH1A1POLBKMT2A | |
| SCHEMBL5236981 | 0.86 | THRB (0.34) | THRATHRBALDH1A1POLBKDM4E | |
| SCHEMBL5234729 | 0.86 | THRB (0.36) | THRATHRBKDM4E | |
| SCHEMBL5238562 | 0.85 | MAPK8 (0.39) | ALDH1A1KMT2AKDM4ETSHR | |
| SCHEMBL5237505 | 0.85 | DPP4 (0.44) | DPP4ALDH1A1KMT2AKDM4ETSHR | |
| SCHEMBL5234366 | 0.85 | ALDH1A1 (0.33) | THRATHRBALDH1A1KDM4EHTT | |
| SCHEMBL5237435 | 0.85 | DPP4 (0.38) | DPP4ALDH1A1KMT2AKDM4ETSHR | |
| SCHEMBL5236379 | 0.85 | DPP4 (0.43) | THRATHRBDPP4ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1355886-B1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2007-07-11 | — | — | EP | disclosed |
| US-20040082607-A1 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082607-A1 | Fused heterocyclic compounds | DPP7, DPP4, METAP1 | THRA 1886/4885THRB 1540/4885DPP4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.